Edition:
India

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

9.13USD
2:02am IST
Change (% chg)

$0.84 (+10.13%)
Prev Close
$8.29
Open
$8.43
Day's High
$9.78
Day's Low
$8.43
Volume
382,007
Avg. Vol
103,797
52-wk High
$9.78
52-wk Low
$2.54

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.53 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article

Fate Therapeutics reports Q2 2016 financial results
Tuesday, 9 Aug 2016 

Fate Therapeutics Inc : Fate Therapeutics reports second quarter 2016 financial results . Q2 revenue $1.0 million versus I/B/E/S view $866,000 . Says Ind Filing For Allogeneic Memory Like NK cell cancer immunotherapy planned for 2016 .Qtrly loss per share $0.29.  Full Article

Fate Therapeutics says $10.3 million common stock private placement
Monday, 8 Aug 2016 

Fate Therapeutics Inc: Fate Therapeutics announces $10.3 million common stock private placement . Investors have agreed to purchase 5.3 million shares of company's common stock at a price of $1.96 per share .Expects to use proceeds from transaction primarily to advance its pipeline of programmed cellular immunotherapies among others.  Full Article

Fate Therapeutics announces FDA fast track designation for Protmune
Monday, 20 Jun 2016 

Fate Therapeutics Inc : Says FDA has granted fast track designation for Protmune .Fate Therapeutics announces FDA fast track designation for Protmune.  Full Article

Fate Therapeutics qtrly net loss $0.29 per share
Tuesday, 10 May 2016 

Fate Therapeutics Inc : Qtrly net loss per common share, basic and diluted $0.29 . Fate therapeutics reports first quarter 2016 financial results . Q1 revenue $1.3 million .Q1 revenue view $795,000 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

* Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy